Nils Brünner

Professor University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Carit Andersen
Chief Financial Officer

External lecturer, University of Southern Denmark.

Jan Stenvang,
Chief Scientific Officer

MSc, PhD.
Associate Professor, University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Peter Michael Vestlev
Chief Medical Officer

Chief Physician, Oncologist, Region Sjælland.
Previously, consultant for the Danish Medicines Agency.

Nicklas Lindland Roest
Chief Regulatory Officer

MSc. Pharm.

Annie Rasmussen
Chief Cinical Officer

Registered Nurse, Special Diploma.


Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.


Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union